Major French research university with world-leading supramolecular chemistry, strong in organic electronics, 2D materials, prebiotic chemistry, and cancer diagnostics.
The University of Strasbourg is a major French research university with deep strengths in supramolecular chemistry, advanced materials, and molecular life sciences. Their teams design functional molecular architectures — from organic electronic materials and fluorescent nanoparticles to enzyme-mediated self-assembling systems — and apply these to optoelectronics, medical imaging, and drug discovery. They also contribute specialized analytical and modeling expertise to large European research infrastructures in planetary science, geothermal energy, and astronomy. Their work sits at the intersection of fundamental chemistry and real-world applications in health diagnostics, electronics, and materials science.
Coordinated iSwitch (switchable organic electronics), MULTI2DSWITCH (2D material heterostructures), SYNCHRONICS and ResMoSys training networks, and BrightSens (fluorescent nanoparticles).
Participated in GrapheneCore1 (EUR 1M), with graphene appearing as a keyword across both early and recent project periods, alongside 2D materials research.
Three recent-period projects focused on prebiotic chemistry, representing a growing research direction not present in early H2020 work.
QuantSURG (EUR 1.17M, colorectal surgery imaging) plus multiple recent projects on rectal cancer active monitoring, watch-and-wait strategies, and diagnostics.
Keywords include allostery, allosteric inhibitors, structure-based drug design, metabolism, and tubulin/microtubule molecular modeling across multiple projects.
Recent keywords include bio-mimetic, bionics, structural coloration, light management, and photosynthesis-inspired approaches to materials design.
In the early H2020 period (2014–2018), Strasbourg focused heavily on graphene, planetary science infrastructure (EUROPLANET), liver disease/hepatitis research, and foundational supramolecular chemistry training networks. By 2019–2024, the portfolio shifted toward prebiotic chemistry, organic semiconductors, bioconjugation, cancer diagnostics (especially rectal cancer imaging and active monitoring), and bio-inspired materials. The university has clearly moved from broad participation in infrastructure-heavy projects toward more targeted, application-oriented research in molecular medicine and functional materials.
Strasbourg is converging its chemistry strengths toward biomedical applications — expect growing output in molecular diagnostics, bio-inspired functional materials, and origins-of-life chemistry.
Strasbourg plays multiple roles flexibly: they coordinate 30% of their projects, participate actively in 40%, and serve as a third-party specialist in 33% — an unusually high third-party rate suggesting they are frequently called upon for specific expertise within large flagships (EUROfusion, EHVA, EPOS). With 925 unique consortium partners across 49 countries, they function as a major European hub rather than sticking to a tight circle. This makes them an easy organization to integrate into new consortia — they are experienced collaborators who adapt to different project structures.
One of the most broadly connected universities in H2020, with 925 unique partners spanning 49 countries. Their network covers research infrastructures, medical consortia, and materials science flagships across nearly all of Europe and beyond.
Strasbourg's defining strength is its world-class supramolecular chemistry school — this is the university where Jean-Marie Lehn won the Nobel Prize for the field. This gives them unmatched depth in molecular self-assembly, which they apply across electronics, biomedicine, and materials. Their location on the Franco-German border and their high third-party participation rate make them a natural bridge between French and German research ecosystems, and their versatility across roles (coordinator, partner, specialist) means they fit into virtually any consortium configuration.
